nodes	percent_of_prediction	percent_of_DWPC	metapath
Norethindrone—Ethinyl Estradiol—prostate cancer	0.226	1	CrCtD
Norethindrone—polycystic ovary syndrome—Ethinyl Estradiol—prostate cancer	0.19	1	CpDpCtD
Norethindrone—SHBG—prostate cancer	0.0496	0.373	CbGaD
Norethindrone—CYP3A5—prostate cancer	0.0395	0.297	CbGaD
Norethindrone—CYP2C19—prostate cancer	0.0269	0.202	CbGaD
Norethindrone—SHBG—Estrone—prostate cancer	0.0213	0.131	CbGbCtD
Norethindrone—SHBG—Ethinyl Estradiol—prostate cancer	0.019	0.117	CbGbCtD
Norethindrone—CYP3A4—prostate cancer	0.0171	0.128	CbGaD
Norethindrone—Nandrolone decanoate—Estradiol valerate/Dienogest—prostate cancer	0.013	0.0643	CrCrCtD
Norethindrone—Nandrolone phenpropionate—Estradiol valerate/Dienogest—prostate cancer	0.013	0.0643	CrCrCtD
Norethindrone—SHBG—Estradiol—prostate cancer	0.0122	0.0752	CbGbCtD
Norethindrone—Testosterone—Abiraterone—prostate cancer	0.0108	0.0535	CrCrCtD
Norethindrone—Ethinyl Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.00984	0.0486	CrCrCtD
Norethindrone—Mestranol—Estramustine—prostate cancer	0.00878	0.0434	CrCrCtD
Norethindrone—Quinestrol—Estramustine—prostate cancer	0.00878	0.0434	CrCrCtD
Norethindrone—Ethinyl Estradiol—Estramustine—prostate cancer	0.00837	0.0414	CrCrCtD
Norethindrone—Formestane—Estrone—prostate cancer	0.00735	0.0363	CrCrCtD
Norethindrone—ALB—Abiraterone—prostate cancer	0.00699	0.0429	CbGbCtD
Norethindrone—Mestranol—Estrone—prostate cancer	0.00698	0.0345	CrCrCtD
Norethindrone—Quinestrol—Estrone—prostate cancer	0.00698	0.0345	CrCrCtD
Norethindrone—Desogestrel—Ethinyl Estradiol—prostate cancer	0.00696	0.0344	CrCrCtD
Norethindrone—Ethinyl Estradiol—Estrone—prostate cancer	0.00665	0.0329	CrCrCtD
Norethindrone—Formestane—Conjugated Estrogens—prostate cancer	0.00647	0.032	CrCrCtD
Norethindrone—Mestranol—Conjugated Estrogens—prostate cancer	0.00614	0.0304	CrCrCtD
Norethindrone—Quinestrol—Conjugated Estrogens—prostate cancer	0.00614	0.0304	CrCrCtD
Norethindrone—Testosterone Propionate—Estradiol valerate/Dienogest—prostate cancer	0.00608	0.0301	CrCrCtD
Norethindrone—Ethinyl Estradiol—Conjugated Estrogens—prostate cancer	0.00585	0.0289	CrCrCtD
Norethindrone—Etonogestrel—Ethinyl Estradiol—prostate cancer	0.00574	0.0284	CrCrCtD
Norethindrone—CYP3A5—Flutamide—prostate cancer	0.00561	0.0345	CbGbCtD
Norethindrone—CYP2C19—Bicalutamide—prostate cancer	0.00547	0.0336	CbGbCtD
Norethindrone—CYP2C19—Nilutamide—prostate cancer	0.00547	0.0336	CbGbCtD
Norethindrone—Norelgestromin—Ethinyl Estradiol—prostate cancer	0.00543	0.0269	CrCrCtD
Norethindrone—Mestranol—Estradiol—prostate cancer	0.00529	0.0261	CrCrCtD
Norethindrone—Quinestrol—Estradiol—prostate cancer	0.00529	0.0261	CrCrCtD
Norethindrone—Mestranol—Ethinyl Estradiol—prostate cancer	0.00516	0.0255	CrCrCtD
Norethindrone—Quinestrol—Ethinyl Estradiol—prostate cancer	0.00516	0.0255	CrCrCtD
Norethindrone—ALB—Estrone—prostate cancer	0.00505	0.031	CbGbCtD
Norethindrone—Ethinyl Estradiol—Estradiol—prostate cancer	0.00504	0.0249	CrCrCtD
Norethindrone—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00503	0.0309	CbGbCtD
Norethindrone—CYP2C19—Flutamide—prostate cancer	0.00453	0.0278	CbGbCtD
Norethindrone—Levonorgestrel—Ethinyl Estradiol—prostate cancer	0.0045	0.0222	CrCrCtD
Norethindrone—Testosterone—Estramustine—prostate cancer	0.00449	0.0222	CrCrCtD
Norethindrone—CYP3A5—Cabazitaxel—prostate cancer	0.00415	0.0255	CbGbCtD
Norethindrone—Danazol—Ethinyl Estradiol—prostate cancer	0.00415	0.0205	CrCrCtD
Norethindrone—ABCB1—Estramustine—prostate cancer	0.0041	0.0252	CbGbCtD
Norethindrone—CYP3A5—Estrone—prostate cancer	0.00406	0.0249	CbGbCtD
Norethindrone—Testosterone—Estrone—prostate cancer	0.00357	0.0176	CrCrCtD
Norethindrone—CYP3A7-CYP3A51P—Estradiol—prostate cancer	0.00311	0.0191	CbGbCtD
Norethindrone—CYP3A7—Estradiol—prostate cancer	0.00311	0.0191	CbGbCtD
Norethindrone—Methyltestosterone—Ethinyl Estradiol—prostate cancer	0.00296	0.0147	CrCrCtD
Norethindrone—ALB—Estradiol—prostate cancer	0.0029	0.0178	CbGbCtD
Norethindrone—Testosterone—Estradiol—prostate cancer	0.0027	0.0134	CrCrCtD
Norethindrone—ABCB1—Cabazitaxel—prostate cancer	0.0027	0.0166	CbGbCtD
Norethindrone—CYP3A4—Bicalutamide—prostate cancer	0.00264	0.0162	CbGbCtD
Norethindrone—ABCB1—Estrone—prostate cancer	0.00264	0.0162	CbGbCtD
Norethindrone—ALB—Prednisone—prostate cancer	0.00249	0.0153	CbGbCtD
Norethindrone—CYP3A4—Estramustine—prostate cancer	0.00246	0.0151	CbGbCtD
Norethindrone—ABCB1—Ethinyl Estradiol—prostate cancer	0.00235	0.0145	CbGbCtD
Norethindrone—CYP3A5—Estradiol—prostate cancer	0.00233	0.0143	CbGbCtD
Norethindrone—CYP3A4—Abiraterone—prostate cancer	0.00219	0.0135	CbGbCtD
Norethindrone—CYP3A4—Flutamide—prostate cancer	0.00219	0.0135	CbGbCtD
Norethindrone—CYP2C19—Estradiol—prostate cancer	0.00188	0.0116	CbGbCtD
Norethindrone—CYP3A7—Docetaxel—prostate cancer	0.00186	0.0114	CbGbCtD
Norethindrone—CYP3A7-CYP3A51P—Docetaxel—prostate cancer	0.00186	0.0114	CbGbCtD
Norethindrone—ABCB1—Conjugated Estrogens—prostate cancer	0.00173	0.0106	CbGbCtD
Norethindrone—CYP3A4—Cabazitaxel—prostate cancer	0.00162	0.00995	CbGbCtD
Norethindrone—CYP2C19—Prednisone—prostate cancer	0.00162	0.00994	CbGbCtD
Norethindrone—CYP3A4—Estrone—prostate cancer	0.00158	0.00973	CbGbCtD
Norethindrone—ABCB1—Mitoxantrone—prostate cancer	0.00157	0.00965	CbGbCtD
Norethindrone—CYP3A5—Etoposide—prostate cancer	0.00152	0.00935	CbGbCtD
Norethindrone—ABCB1—Estradiol—prostate cancer	0.00152	0.00932	CbGbCtD
Norethindrone—Danazol—Prednisone—prostate cancer	0.00146	0.00721	CrCrCtD
Norethindrone—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00141	0.00867	CbGbCtD
Norethindrone—CYP3A5—Docetaxel—prostate cancer	0.00139	0.00856	CbGbCtD
Norethindrone—ABCB1—Prednisone—prostate cancer	0.0013	0.00802	CbGbCtD
Norethindrone—SHBG—semen—prostate cancer	0.00129	0.278	CbGeAlD
Norethindrone—Cortisone acetate—Prednisone—prostate cancer	0.00123	0.00608	CrCrCtD
Norethindrone—Methyltestosterone—Prednisone—prostate cancer	0.00104	0.00515	CrCrCtD
Norethindrone—CYP3A4—Conjugated Estrogens—prostate cancer	0.00104	0.00636	CbGbCtD
Norethindrone—ABCB1—Etoposide—prostate cancer	0.000991	0.00609	CbGbCtD
Norethindrone—CYP3A4—Mitoxantrone—prostate cancer	0.000941	0.00578	CbGbCtD
Norethindrone—CYP3A4—Estradiol—prostate cancer	0.000909	0.00559	CbGbCtD
Norethindrone—ABCB1—Docetaxel—prostate cancer	0.000906	0.00557	CbGbCtD
Norethindrone—Hydrocortisone—Prednisone—prostate cancer	0.000871	0.00431	CrCrCtD
Norethindrone—CYP3A4—Prednisone—prostate cancer	0.000782	0.0048	CbGbCtD
Norethindrone—ABCB1—Doxorubicin—prostate cancer	0.000676	0.00415	CbGbCtD
Norethindrone—CYP2C19—urine—prostate cancer	0.0006	0.129	CbGeAlD
Norethindrone—CYP3A4—Etoposide—prostate cancer	0.000594	0.00365	CbGbCtD
Norethindrone—CYP3A4—Docetaxel—prostate cancer	0.000543	0.00334	CbGbCtD
Norethindrone—CYP3A4—Doxorubicin—prostate cancer	0.000405	0.00249	CbGbCtD
Norethindrone—CYP3A4—urine—prostate cancer	0.000355	0.0762	CbGeAlD
Norethindrone—SHBG—prostate gland—prostate cancer	0.000324	0.0696	CbGeAlD
Norethindrone—PGR—prostate gland—prostate cancer	0.000292	0.0627	CbGeAlD
Norethindrone—PGR—epithelium—prostate cancer	0.000215	0.0461	CbGeAlD
Norethindrone—CYP3A5—prostate gland—prostate cancer	0.00017	0.0365	CbGeAlD
Norethindrone—SHBG—bone marrow—prostate cancer	0.000167	0.0359	CbGeAlD
Norethindrone—SHBG—testis—prostate cancer	0.000143	0.0307	CbGeAlD
Norethindrone—PGR—testis—prostate cancer	0.000129	0.0276	CbGeAlD
Norethindrone—ALB—testis—prostate cancer	0.000118	0.0253	CbGeAlD
Norethindrone—CYP3A5—renal system—prostate cancer	0.000116	0.0249	CbGeAlD
Norethindrone—PGR—lymph node—prostate cancer	9.33e-05	0.02	CbGeAlD
Norethindrone—ABCB1—prostate gland—prostate cancer	9.02e-05	0.0194	CbGeAlD
Norethindrone—CYP3A4—renal system—prostate cancer	8.69e-05	0.0187	CbGeAlD
Norethindrone—ALB—lymph node—prostate cancer	8.55e-05	0.0184	CbGeAlD
Norethindrone—ABCB1—seminal vesicle—prostate cancer	7.63e-05	0.0164	CbGeAlD
Norethindrone—Levonorgestrel—SRD5A1—prostate cancer	7.57e-05	0.0459	CrCbGaD
Norethindrone—ABCB1—epithelium—prostate cancer	6.63e-05	0.0142	CbGeAlD
Norethindrone—Stanozolol—AR—prostate cancer	6.32e-05	0.0383	CrCbGaD
Norethindrone—ABCB1—renal system—prostate cancer	6.15e-05	0.0132	CbGeAlD
Norethindrone—ABCB1—urethra—prostate cancer	6.04e-05	0.013	CbGeAlD
Norethindrone—Ethinyl Estradiol—AOX1—prostate cancer	5.83e-05	0.0353	CrCbGaD
Norethindrone—Oxandrolone—AR—prostate cancer	5.69e-05	0.0345	CrCbGaD
Norethindrone—ABCB1—bone marrow—prostate cancer	4.65e-05	0.00998	CbGeAlD
Norethindrone—Desogestrel—SHBG—prostate cancer	4.47e-05	0.0271	CrCbGaD
Norethindrone—Nandrolone phenpropionate—AR—prostate cancer	4.46e-05	0.027	CrCbGaD
Norethindrone—Quinestrol—ESR1—prostate cancer	4.04e-05	0.0245	CrCbGaD
Norethindrone—ABCB1—testis—prostate cancer	3.97e-05	0.00853	CbGeAlD
Norethindrone—Gestodene—CYP3A5—prostate cancer	3.86e-05	0.0234	CrCbGaD
Norethindrone—Testosterone Propionate—CYP17A1—prostate cancer	3.8e-05	0.023	CrCbGaD
Norethindrone—Hydrocortisone—ANXA1—prostate cancer	3.73e-05	0.0226	CrCbGaD
Norethindrone—Nandrolone phenpropionate—CYP19A1—prostate cancer	3.73e-05	0.0226	CrCbGaD
Norethindrone—Testosterone—CYP3A43—prostate cancer	3.63e-05	0.022	CrCbGaD
Norethindrone—Etonogestrel—SHBG—prostate cancer	3.62e-05	0.0219	CrCbGaD
Norethindrone—Nandrolone decanoate—AR—prostate cancer	3.38e-05	0.0205	CrCbGaD
Norethindrone—Ethynodiol—ESR1—prostate cancer	3.32e-05	0.0201	CrCbGaD
Norethindrone—Allylestrenol—ESR1—prostate cancer	3.14e-05	0.019	CrCbGaD
Norethindrone—Testosterone Propionate—COMT—prostate cancer	3.1e-05	0.0188	CrCbGaD
Norethindrone—Mestranol—ESR1—prostate cancer	3.06e-05	0.0185	CrCbGaD
Norethindrone—Desogestrel—ESR1—prostate cancer	3.02e-05	0.0183	CrCbGaD
Norethindrone—ABCB1—lymph node—prostate cancer	2.88e-05	0.00619	CbGeAlD
Norethindrone—Norgestimate—ESR1—prostate cancer	2.83e-05	0.0171	CrCbGaD
Norethindrone—Nandrolone decanoate—CYP19A1—prostate cancer	2.83e-05	0.0171	CrCbGaD
Norethindrone—Drospirenone—AR—prostate cancer	2.75e-05	0.0167	CrCbGaD
Norethindrone—Levonorgestrel—SHBG—prostate cancer	2.56e-05	0.0155	CrCbGaD
Norethindrone—Etonogestrel—ESR1—prostate cancer	2.45e-05	0.0148	CrCbGaD
Norethindrone—Fluoxymesterone—SHBG—prostate cancer	2.44e-05	0.0148	CrCbGaD
Norethindrone—Ethinyl Estradiol—ESR2—prostate cancer	2.37e-05	0.0143	CrCbGaD
Norethindrone—Danazol—SHBG—prostate cancer	2.33e-05	0.0141	CrCbGaD
Norethindrone—Testosterone Propionate—AR—prostate cancer	2.31e-05	0.014	CrCbGaD
Norethindrone—Levonorgestrel—AR—prostate cancer	2.25e-05	0.0136	CrCbGaD
Norethindrone—Cortisone acetate—NR3C1—prostate cancer	2.22e-05	0.0134	CrCbGaD
Norethindrone—Ethinyl Estradiol—SHBG—prostate cancer	2.16e-05	0.0131	CrCbGaD
Norethindrone—Fluoxymesterone—AR—prostate cancer	2.14e-05	0.013	CrCbGaD
Norethindrone—Danazol—AR—prostate cancer	2.05e-05	0.0124	CrCbGaD
Norethindrone—Methyltestosterone—SHBG—prostate cancer	1.97e-05	0.0119	CrCbGaD
Norethindrone—Levonorgestrel—CYP19A1—prostate cancer	1.88e-05	0.0114	CrCbGaD
Norethindrone—Renal impairment—Epirubicin—prostate cancer	1.83e-05	0.000326	CcSEcCtD
Norethindrone—Hepatobiliary disease—Capecitabine—prostate cancer	1.82e-05	0.000324	CcSEcCtD
Norethindrone—Hypersensitivity—Conjugated Estrogens—prostate cancer	1.81e-05	0.000323	CcSEcCtD
Norethindrone—Purpura—Epirubicin—prostate cancer	1.8e-05	0.000321	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Epirubicin—prostate cancer	1.79e-05	0.00032	CcSEcCtD
Norethindrone—Haemoglobin—Docetaxel—prostate cancer	1.79e-05	0.000319	CcSEcCtD
Norethindrone—Nausea—Ethinyl Estradiol—prostate cancer	1.79e-05	0.000319	CcSEcCtD
Norethindrone—Haemorrhage—Docetaxel—prostate cancer	1.78e-05	0.000318	CcSEcCtD
Norethindrone—Hepatitis—Docetaxel—prostate cancer	1.78e-05	0.000318	CcSEcCtD
Norethindrone—Asthenia—Goserelin—prostate cancer	1.78e-05	0.000317	CcSEcCtD
Norethindrone—Skin disorder—Mitoxantrone—prostate cancer	1.78e-05	0.000317	CcSEcCtD
Norethindrone—Insomnia—Estradiol—prostate cancer	1.78e-05	0.000317	CcSEcCtD
Norethindrone—Asthenia—Conjugated Estrogens—prostate cancer	1.76e-05	0.000314	CcSEcCtD
Norethindrone—Pruritus—Goserelin—prostate cancer	1.75e-05	0.000313	CcSEcCtD
Norethindrone—Connective tissue disorder—Docetaxel—prostate cancer	1.75e-05	0.000312	CcSEcCtD
Norethindrone—Somnolence—Estradiol—prostate cancer	1.75e-05	0.000312	CcSEcCtD
Norethindrone—Weight increased—Prednisone—prostate cancer	1.75e-05	0.000312	CcSEcCtD
Norethindrone—Progesterone—CYP17A1—prostate cancer	1.75e-05	0.0106	CrCbGaD
Norethindrone—Pruritus—Conjugated Estrogens—prostate cancer	1.74e-05	0.00031	CcSEcCtD
Norethindrone—Pain in extremity—Epirubicin—prostate cancer	1.74e-05	0.00031	CcSEcCtD
Norethindrone—Haemoglobin—Capecitabine—prostate cancer	1.73e-05	0.000309	CcSEcCtD
Norethindrone—Levonorgestrel—ESR1—prostate cancer	1.73e-05	0.0105	CrCbGaD
Norethindrone—Dyspepsia—Estradiol—prostate cancer	1.73e-05	0.000309	CcSEcCtD
Norethindrone—Methyltestosterone—AR—prostate cancer	1.73e-05	0.0105	CrCbGaD
Norethindrone—Haemorrhage—Capecitabine—prostate cancer	1.72e-05	0.000308	CcSEcCtD
Norethindrone—Hepatitis—Capecitabine—prostate cancer	1.72e-05	0.000308	CcSEcCtD
Norethindrone—Danazol—CYP19A1—prostate cancer	1.71e-05	0.0104	CrCbGaD
Norethindrone—Migraine—Epirubicin—prostate cancer	1.71e-05	0.000305	CcSEcCtD
Norethindrone—Affect lability—Epirubicin—prostate cancer	1.71e-05	0.000305	CcSEcCtD
Norethindrone—Depression—Prednisone—prostate cancer	1.71e-05	0.000304	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Estradiol—prostate cancer	1.7e-05	0.000303	CcSEcCtD
Norethindrone—Connective tissue disorder—Capecitabine—prostate cancer	1.7e-05	0.000302	CcSEcCtD
Norethindrone—Fatigue—Estradiol—prostate cancer	1.69e-05	0.000302	CcSEcCtD
Norethindrone—Renal impairment—Doxorubicin—prostate cancer	1.69e-05	0.000301	CcSEcCtD
Norethindrone—Acute coronary syndrome—Prednisone—prostate cancer	1.69e-05	0.000301	CcSEcCtD
Norethindrone—Erythema multiforme—Docetaxel—prostate cancer	1.68e-05	0.0003	CcSEcCtD
Norethindrone—Myocardial infarction—Prednisone—prostate cancer	1.68e-05	0.000299	CcSEcCtD
Norethindrone—Purpura—Doxorubicin—prostate cancer	1.67e-05	0.000297	CcSEcCtD
Norethindrone—Progesterone—SLC22A3—prostate cancer	1.66e-05	0.0101	CrCbGaD
Norethindrone—Anaphylactoid reaction—Doxorubicin—prostate cancer	1.66e-05	0.000296	CcSEcCtD
Norethindrone—Fluoxymesterone—ESR1—prostate cancer	1.65e-05	0.00999	CrCbGaD
Norethindrone—Mood swings—Epirubicin—prostate cancer	1.65e-05	0.000293	CcSEcCtD
Norethindrone—Dizziness—Goserelin—prostate cancer	1.64e-05	0.000292	CcSEcCtD
Norethindrone—Erythema multiforme—Capecitabine—prostate cancer	1.63e-05	0.000291	CcSEcCtD
Norethindrone—Somnolence—Mitoxantrone—prostate cancer	1.63e-05	0.00029	CcSEcCtD
Norethindrone—Dizziness—Conjugated Estrogens—prostate cancer	1.62e-05	0.00029	CcSEcCtD
Norethindrone—Convulsion—Etoposide—prostate cancer	1.62e-05	0.000288	CcSEcCtD
Norethindrone—Dyspepsia—Mitoxantrone—prostate cancer	1.61e-05	0.000287	CcSEcCtD
Norethindrone—Immune system disorder—Docetaxel—prostate cancer	1.61e-05	0.000287	CcSEcCtD
Norethindrone—Pain in extremity—Doxorubicin—prostate cancer	1.61e-05	0.000287	CcSEcCtD
Norethindrone—Gastrointestinal pain—Estradiol—prostate cancer	1.61e-05	0.000287	CcSEcCtD
Norethindrone—Allylestrenol—CYP3A4—prostate cancer	1.6e-05	0.00971	CrCbGaD
Norethindrone—Affect lability—Doxorubicin—prostate cancer	1.58e-05	0.000282	CcSEcCtD
Norethindrone—Migraine—Doxorubicin—prostate cancer	1.58e-05	0.000282	CcSEcCtD
Norethindrone—Fatigue—Mitoxantrone—prostate cancer	1.58e-05	0.000282	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	1.58e-05	0.000281	CcSEcCtD
Norethindrone—Vomiting—Goserelin—prostate cancer	1.58e-05	0.000281	CcSEcCtD
Norethindrone—Danazol—ESR1—prostate cancer	1.58e-05	0.00955	CrCbGaD
Norethindrone—Alopecia—Docetaxel—prostate cancer	1.57e-05	0.000281	CcSEcCtD
Norethindrone—Testosterone—SLC22A3—prostate cancer	1.57e-05	0.00954	CrCbGaD
Norethindrone—Breast disorder—Epirubicin—prostate cancer	1.57e-05	0.00028	CcSEcCtD
Norethindrone—Rash—Goserelin—prostate cancer	1.56e-05	0.000279	CcSEcCtD
Norethindrone—Dermatitis—Goserelin—prostate cancer	1.56e-05	0.000279	CcSEcCtD
Norethindrone—Vomiting—Conjugated Estrogens—prostate cancer	1.56e-05	0.000278	CcSEcCtD
Norethindrone—Urticaria—Estradiol—prostate cancer	1.56e-05	0.000278	CcSEcCtD
Norethindrone—Mental disorder—Docetaxel—prostate cancer	1.56e-05	0.000278	CcSEcCtD
Norethindrone—Immune system disorder—Capecitabine—prostate cancer	1.56e-05	0.000278	CcSEcCtD
Norethindrone—Abdominal pain—Estradiol—prostate cancer	1.55e-05	0.000277	CcSEcCtD
Norethindrone—Headache—Goserelin—prostate cancer	1.55e-05	0.000277	CcSEcCtD
Norethindrone—Rash—Conjugated Estrogens—prostate cancer	1.55e-05	0.000276	CcSEcCtD
Norethindrone—Dermatitis—Conjugated Estrogens—prostate cancer	1.55e-05	0.000276	CcSEcCtD
Norethindrone—Haemoglobin—Prednisone—prostate cancer	1.54e-05	0.000275	CcSEcCtD
Norethindrone—Headache—Conjugated Estrogens—prostate cancer	1.54e-05	0.000274	CcSEcCtD
Norethindrone—Haemorrhage—Prednisone—prostate cancer	1.54e-05	0.000274	CcSEcCtD
Norethindrone—Alopecia—Capecitabine—prostate cancer	1.52e-05	0.000272	CcSEcCtD
Norethindrone—Anaphylactic shock—Etoposide—prostate cancer	1.52e-05	0.000272	CcSEcCtD
Norethindrone—Mood swings—Doxorubicin—prostate cancer	1.52e-05	0.000272	CcSEcCtD
Norethindrone—Abdominal distension—Epirubicin—prostate cancer	1.51e-05	0.00027	CcSEcCtD
Norethindrone—Mental disorder—Capecitabine—prostate cancer	1.51e-05	0.00027	CcSEcCtD
Norethindrone—Connective tissue disorder—Prednisone—prostate cancer	1.51e-05	0.000269	CcSEcCtD
Norethindrone—Gastrointestinal pain—Mitoxantrone—prostate cancer	1.5e-05	0.000267	CcSEcCtD
Norethindrone—Hydrocortisone—SHBG—prostate cancer	1.48e-05	0.009	CrCbGaD
Norethindrone—Flatulence—Capecitabine—prostate cancer	1.48e-05	0.000264	CcSEcCtD
Norethindrone—Skin disorder—Etoposide—prostate cancer	1.48e-05	0.000264	CcSEcCtD
Norethindrone—Nausea—Goserelin—prostate cancer	1.47e-05	0.000263	CcSEcCtD
Norethindrone—Nausea—Conjugated Estrogens—prostate cancer	1.46e-05	0.00026	CcSEcCtD
Norethindrone—Ethinyl Estradiol—ESR1—prostate cancer	1.46e-05	0.00884	CrCbGaD
Norethindrone—Urticaria—Mitoxantrone—prostate cancer	1.45e-05	0.000259	CcSEcCtD
Norethindrone—Breast disorder—Doxorubicin—prostate cancer	1.45e-05	0.000259	CcSEcCtD
Norethindrone—Fluoxymesterone—NR3C1—prostate cancer	1.45e-05	0.0088	CrCbGaD
Norethindrone—Hypersensitivity—Estradiol—prostate cancer	1.45e-05	0.000258	CcSEcCtD
Norethindrone—Abdominal pain—Mitoxantrone—prostate cancer	1.45e-05	0.000258	CcSEcCtD
Norethindrone—Methyltestosterone—CYP19A1—prostate cancer	1.45e-05	0.00877	CrCbGaD
Norethindrone—Asthenia—Estradiol—prostate cancer	1.41e-05	0.000251	CcSEcCtD
Norethindrone—Abdominal distension—Doxorubicin—prostate cancer	1.4e-05	0.000249	CcSEcCtD
Norethindrone—Pruritus—Estradiol—prostate cancer	1.39e-05	0.000248	CcSEcCtD
Norethindrone—Immune system disorder—Prednisone—prostate cancer	1.39e-05	0.000248	CcSEcCtD
Norethindrone—Photosensitivity reaction—Epirubicin—prostate cancer	1.37e-05	0.000244	CcSEcCtD
Norethindrone—Weight increased—Epirubicin—prostate cancer	1.37e-05	0.000244	CcSEcCtD
Norethindrone—Alopecia—Prednisone—prostate cancer	1.36e-05	0.000242	CcSEcCtD
Norethindrone—Somnolence—Etoposide—prostate cancer	1.35e-05	0.000241	CcSEcCtD
Norethindrone—Hypersensitivity—Mitoxantrone—prostate cancer	1.35e-05	0.000241	CcSEcCtD
Norethindrone—Mental disorder—Prednisone—prostate cancer	1.35e-05	0.00024	CcSEcCtD
Norethindrone—Convulsion—Docetaxel—prostate cancer	1.34e-05	0.00024	CcSEcCtD
Norethindrone—Drowsiness—Epirubicin—prostate cancer	1.34e-05	0.000239	CcSEcCtD
Norethindrone—Renal failure—Epirubicin—prostate cancer	1.32e-05	0.000235	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Etoposide—prostate cancer	1.31e-05	0.000235	CcSEcCtD
Norethindrone—Asthenia—Mitoxantrone—prostate cancer	1.31e-05	0.000234	CcSEcCtD
Norethindrone—Fatigue—Etoposide—prostate cancer	1.31e-05	0.000234	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	1.31e-05	0.000234	CcSEcCtD
Norethindrone—Dizziness—Estradiol—prostate cancer	1.3e-05	0.000232	CcSEcCtD
Norethindrone—Cortisone acetate—CYP3A4—prostate cancer	1.29e-05	0.00779	CrCbGaD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	1.27e-05	0.000226	CcSEcCtD
Norethindrone—Photosensitivity reaction—Doxorubicin—prostate cancer	1.27e-05	0.000226	CcSEcCtD
Norethindrone—Hepatobiliary disease—Epirubicin—prostate cancer	1.27e-05	0.000226	CcSEcCtD
Norethindrone—Anaphylactic shock—Docetaxel—prostate cancer	1.27e-05	0.000226	CcSEcCtD
Norethindrone—Oedema—Docetaxel—prostate cancer	1.27e-05	0.000226	CcSEcCtD
Norethindrone—Weight increased—Doxorubicin—prostate cancer	1.26e-05	0.000225	CcSEcCtD
Norethindrone—Vomiting—Estradiol—prostate cancer	1.25e-05	0.000223	CcSEcCtD
Norethindrone—Etonogestrel—CYP3A4—prostate cancer	1.25e-05	0.00756	CrCbGaD
Norethindrone—Gastrointestinal pain—Etoposide—prostate cancer	1.25e-05	0.000222	CcSEcCtD
Norethindrone—Rash—Estradiol—prostate cancer	1.24e-05	0.000221	CcSEcCtD
Norethindrone—Drowsiness—Doxorubicin—prostate cancer	1.24e-05	0.000221	CcSEcCtD
Norethindrone—Dermatitis—Estradiol—prostate cancer	1.24e-05	0.000221	CcSEcCtD
Norethindrone—Headache—Estradiol—prostate cancer	1.23e-05	0.00022	CcSEcCtD
Norethindrone—Skin disorder—Docetaxel—prostate cancer	1.23e-05	0.000219	CcSEcCtD
Norethindrone—Oedema—Capecitabine—prostate cancer	1.23e-05	0.000219	CcSEcCtD
Norethindrone—Renal failure—Doxorubicin—prostate cancer	1.22e-05	0.000217	CcSEcCtD
Norethindrone—Urticaria—Etoposide—prostate cancer	1.21e-05	0.000216	CcSEcCtD
Norethindrone—Progesterone—SHBG—prostate cancer	1.21e-05	0.00733	CrCbGaD
Norethindrone—Progesterone—CYP1B1—prostate cancer	1.21e-05	0.00733	CrCbGaD
Norethindrone—Haemoglobin—Epirubicin—prostate cancer	1.21e-05	0.000215	CcSEcCtD
Norethindrone—Abdominal pain—Etoposide—prostate cancer	1.2e-05	0.000215	CcSEcCtD
Norethindrone—Hepatitis—Epirubicin—prostate cancer	1.2e-05	0.000214	CcSEcCtD
Norethindrone—Haemorrhage—Epirubicin—prostate cancer	1.2e-05	0.000214	CcSEcCtD
Norethindrone—Progesterone—SLC22A1—prostate cancer	1.19e-05	0.00723	CrCbGaD
Norethindrone—Skin disorder—Capecitabine—prostate cancer	1.19e-05	0.000212	CcSEcCtD
Norethindrone—Hydrocortisone—CYP3A5—prostate cancer	1.18e-05	0.00717	CrCbGaD
Norethindrone—Connective tissue disorder—Epirubicin—prostate cancer	1.18e-05	0.000211	CcSEcCtD
Norethindrone—Hepatobiliary disease—Doxorubicin—prostate cancer	1.17e-05	0.000209	CcSEcCtD
Norethindrone—Nausea—Estradiol—prostate cancer	1.17e-05	0.000208	CcSEcCtD
Norethindrone—Vomiting—Mitoxantrone—prostate cancer	1.16e-05	0.000208	CcSEcCtD
Norethindrone—Convulsion—Prednisone—prostate cancer	1.16e-05	0.000207	CcSEcCtD
Norethindrone—Rash—Mitoxantrone—prostate cancer	1.15e-05	0.000206	CcSEcCtD
Norethindrone—Dermatitis—Mitoxantrone—prostate cancer	1.15e-05	0.000206	CcSEcCtD
Norethindrone—Headache—Mitoxantrone—prostate cancer	1.15e-05	0.000205	CcSEcCtD
Norethindrone—Insomnia—Docetaxel—prostate cancer	1.14e-05	0.000204	CcSEcCtD
Norethindrone—Testosterone—SHBG—prostate cancer	1.14e-05	0.00693	CrCbGaD
Norethindrone—Testosterone—CYP1B1—prostate cancer	1.14e-05	0.00693	CrCbGaD
Norethindrone—Erythema multiforme—Epirubicin—prostate cancer	1.14e-05	0.000203	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	1.13e-05	0.000202	CcSEcCtD
Norethindrone—Testosterone—SLC22A1—prostate cancer	1.13e-05	0.00684	CrCbGaD
Norethindrone—Somnolence—Docetaxel—prostate cancer	1.13e-05	0.000201	CcSEcCtD
Norethindrone—Hypersensitivity—Etoposide—prostate cancer	1.12e-05	0.0002	CcSEcCtD
Norethindrone—Haemoglobin—Doxorubicin—prostate cancer	1.12e-05	0.000199	CcSEcCtD
Norethindrone—Dyspepsia—Docetaxel—prostate cancer	1.11e-05	0.000199	CcSEcCtD
Norethindrone—Haemorrhage—Doxorubicin—prostate cancer	1.11e-05	0.000198	CcSEcCtD
Norethindrone—Hepatitis—Doxorubicin—prostate cancer	1.11e-05	0.000198	CcSEcCtD
Norethindrone—Insomnia—Capecitabine—prostate cancer	1.11e-05	0.000198	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Docetaxel—prostate cancer	1.09e-05	0.000195	CcSEcCtD
Norethindrone—Asthenia—Etoposide—prostate cancer	1.09e-05	0.000195	CcSEcCtD
Norethindrone—Connective tissue disorder—Doxorubicin—prostate cancer	1.09e-05	0.000195	CcSEcCtD
Norethindrone—Anaphylactic shock—Prednisone—prostate cancer	1.09e-05	0.000195	CcSEcCtD
Norethindrone—Oedema—Prednisone—prostate cancer	1.09e-05	0.000195	CcSEcCtD
Norethindrone—Fatigue—Docetaxel—prostate cancer	1.09e-05	0.000195	CcSEcCtD
Norethindrone—Nausea—Mitoxantrone—prostate cancer	1.09e-05	0.000194	CcSEcCtD
Norethindrone—Immune system disorder—Epirubicin—prostate cancer	1.09e-05	0.000194	CcSEcCtD
Norethindrone—Dyspepsia—Capecitabine—prostate cancer	1.08e-05	0.000192	CcSEcCtD
Norethindrone—Pruritus—Etoposide—prostate cancer	1.08e-05	0.000192	CcSEcCtD
Norethindrone—Alopecia—Epirubicin—prostate cancer	1.06e-05	0.000189	CcSEcCtD
Norethindrone—Progesterone—AR—prostate cancer	1.06e-05	0.00643	CrCbGaD
Norethindrone—Skin disorder—Prednisone—prostate cancer	1.06e-05	0.000189	CcSEcCtD
Norethindrone—Drospirenone—PTGS2—prostate cancer	1.06e-05	0.00642	CrCbGaD
Norethindrone—Gastrointestinal disorder—Capecitabine—prostate cancer	1.06e-05	0.000189	CcSEcCtD
Norethindrone—Fatigue—Capecitabine—prostate cancer	1.06e-05	0.000188	CcSEcCtD
Norethindrone—Mental disorder—Epirubicin—prostate cancer	1.05e-05	0.000188	CcSEcCtD
Norethindrone—Erythema multiforme—Doxorubicin—prostate cancer	1.05e-05	0.000188	CcSEcCtD
Norethindrone—Gastrointestinal pain—Docetaxel—prostate cancer	1.04e-05	0.000185	CcSEcCtD
Norethindrone—Flatulence—Epirubicin—prostate cancer	1.03e-05	0.000184	CcSEcCtD
Norethindrone—Tension—Epirubicin—prostate cancer	1.03e-05	0.000183	CcSEcCtD
Norethindrone—Nervousness—Epirubicin—prostate cancer	1.02e-05	0.000181	CcSEcCtD
Norethindrone—Dizziness—Etoposide—prostate cancer	1.01e-05	0.00018	CcSEcCtD
Norethindrone—Immune system disorder—Doxorubicin—prostate cancer	1e-05	0.000179	CcSEcCtD
Norethindrone—Testosterone—AR—prostate cancer	1e-05	0.00608	CrCbGaD
Norethindrone—Gastrointestinal pain—Capecitabine—prostate cancer	1e-05	0.000179	CcSEcCtD
Norethindrone—Abdominal pain—Docetaxel—prostate cancer	1e-05	0.000178	CcSEcCtD
Norethindrone—Insomnia—Prednisone—prostate cancer	9.87e-06	0.000176	CcSEcCtD
Norethindrone—Alopecia—Doxorubicin—prostate cancer	9.83e-06	0.000175	CcSEcCtD
Norethindrone—Mental disorder—Doxorubicin—prostate cancer	9.74e-06	0.000174	CcSEcCtD
Norethindrone—Urticaria—Capecitabine—prostate cancer	9.74e-06	0.000174	CcSEcCtD
Norethindrone—Abdominal pain—Capecitabine—prostate cancer	9.69e-06	0.000173	CcSEcCtD
Norethindrone—Vomiting—Etoposide—prostate cancer	9.68e-06	0.000173	CcSEcCtD
Norethindrone—Progesterone—CYP3A5—prostate cancer	9.63e-06	0.00584	CrCbGaD
Norethindrone—Dyspepsia—Prednisone—prostate cancer	9.61e-06	0.000171	CcSEcCtD
Norethindrone—Rash—Etoposide—prostate cancer	9.6e-06	0.000171	CcSEcCtD
Norethindrone—Dermatitis—Etoposide—prostate cancer	9.59e-06	0.000171	CcSEcCtD
Norethindrone—Headache—Etoposide—prostate cancer	9.54e-06	0.00017	CcSEcCtD
Norethindrone—Flatulence—Doxorubicin—prostate cancer	9.54e-06	0.00017	CcSEcCtD
Norethindrone—Tension—Doxorubicin—prostate cancer	9.5e-06	0.000169	CcSEcCtD
Norethindrone—Fatigue—Prednisone—prostate cancer	9.41e-06	0.000168	CcSEcCtD
Norethindrone—Nervousness—Doxorubicin—prostate cancer	9.4e-06	0.000168	CcSEcCtD
Norethindrone—Hypersensitivity—Docetaxel—prostate cancer	9.33e-06	0.000166	CcSEcCtD
Norethindrone—Progesterone—CYP2A6—prostate cancer	9.32e-06	0.00565	CrCbGaD
Norethindrone—Testosterone—CYP3A5—prostate cancer	9.11e-06	0.00552	CrCbGaD
Norethindrone—Asthenia—Docetaxel—prostate cancer	9.08e-06	0.000162	CcSEcCtD
Norethindrone—Convulsion—Epirubicin—prostate cancer	9.06e-06	0.000162	CcSEcCtD
Norethindrone—Nausea—Etoposide—prostate cancer	9.05e-06	0.000161	CcSEcCtD
Norethindrone—Hypersensitivity—Capecitabine—prostate cancer	9.03e-06	0.000161	CcSEcCtD
Norethindrone—Pruritus—Docetaxel—prostate cancer	8.96e-06	0.00016	CcSEcCtD
Norethindrone—Gastrointestinal pain—Prednisone—prostate cancer	8.93e-06	0.000159	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	8.84e-06	0.000158	CcSEcCtD
Norethindrone—Levonorgestrel—CYP3A4—prostate cancer	8.83e-06	0.00535	CrCbGaD
Norethindrone—Hydrocortisone—NR3C1—prostate cancer	8.83e-06	0.00535	CrCbGaD
Norethindrone—Asthenia—Capecitabine—prostate cancer	8.79e-06	0.000157	CcSEcCtD
Norethindrone—Urticaria—Prednisone—prostate cancer	8.67e-06	0.000155	CcSEcCtD
Norethindrone—Pruritus—Capecitabine—prostate cancer	8.67e-06	0.000155	CcSEcCtD
Norethindrone—Abdominal pain—Prednisone—prostate cancer	8.63e-06	0.000154	CcSEcCtD
Norethindrone—Oedema—Epirubicin—prostate cancer	8.54e-06	0.000152	CcSEcCtD
Norethindrone—Anaphylactic shock—Epirubicin—prostate cancer	8.54e-06	0.000152	CcSEcCtD
Norethindrone—Testosterone—CYP19A1—prostate cancer	8.39e-06	0.00509	CrCbGaD
Norethindrone—Convulsion—Doxorubicin—prostate cancer	8.39e-06	0.00015	CcSEcCtD
Norethindrone—Dizziness—Docetaxel—prostate cancer	8.37e-06	0.000149	CcSEcCtD
Norethindrone—Skin disorder—Epirubicin—prostate cancer	8.29e-06	0.000148	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	8.18e-06	0.000146	CcSEcCtD
Norethindrone—Progesterone—ESR1—prostate cancer	8.17e-06	0.00495	CrCbGaD
Norethindrone—Dizziness—Capecitabine—prostate cancer	8.1e-06	0.000145	CcSEcCtD
Norethindrone—Vomiting—Docetaxel—prostate cancer	8.05e-06	0.000144	CcSEcCtD
Norethindrone—Hypersensitivity—Prednisone—prostate cancer	8.04e-06	0.000143	CcSEcCtD
Norethindrone—Danazol—CYP3A4—prostate cancer	8.04e-06	0.00487	CrCbGaD
Norethindrone—Rash—Docetaxel—prostate cancer	7.98e-06	0.000142	CcSEcCtD
Norethindrone—Dermatitis—Docetaxel—prostate cancer	7.97e-06	0.000142	CcSEcCtD
Norethindrone—Headache—Docetaxel—prostate cancer	7.93e-06	0.000141	CcSEcCtD
Norethindrone—Oedema—Doxorubicin—prostate cancer	7.9e-06	0.000141	CcSEcCtD
Norethindrone—Anaphylactic shock—Doxorubicin—prostate cancer	7.9e-06	0.000141	CcSEcCtD
Norethindrone—Asthenia—Prednisone—prostate cancer	7.83e-06	0.00014	CcSEcCtD
Norethindrone—Vomiting—Capecitabine—prostate cancer	7.79e-06	0.000139	CcSEcCtD
Norethindrone—Rash—Capecitabine—prostate cancer	7.73e-06	0.000138	CcSEcCtD
Norethindrone—Pruritus—Prednisone—prostate cancer	7.72e-06	0.000138	CcSEcCtD
Norethindrone—Insomnia—Epirubicin—prostate cancer	7.72e-06	0.000138	CcSEcCtD
Norethindrone—Dermatitis—Capecitabine—prostate cancer	7.72e-06	0.000138	CcSEcCtD
Norethindrone—Headache—Capecitabine—prostate cancer	7.68e-06	0.000137	CcSEcCtD
Norethindrone—Skin disorder—Doxorubicin—prostate cancer	7.67e-06	0.000137	CcSEcCtD
Norethindrone—Somnolence—Epirubicin—prostate cancer	7.59e-06	0.000135	CcSEcCtD
Norethindrone—Nausea—Docetaxel—prostate cancer	7.52e-06	0.000134	CcSEcCtD
Norethindrone—Dyspepsia—Epirubicin—prostate cancer	7.52e-06	0.000134	CcSEcCtD
Norethindrone—Ethinyl Estradiol—CYP3A4—prostate cancer	7.44e-06	0.00451	CrCbGaD
Norethindrone—Gastrointestinal disorder—Epirubicin—prostate cancer	7.37e-06	0.000131	CcSEcCtD
Norethindrone—Fatigue—Epirubicin—prostate cancer	7.36e-06	0.000131	CcSEcCtD
Norethindrone—Nausea—Capecitabine—prostate cancer	7.28e-06	0.00013	CcSEcCtD
Norethindrone—Dizziness—Prednisone—prostate cancer	7.22e-06	0.000129	CcSEcCtD
Norethindrone—Progesterone—NR3C1—prostate cancer	7.19e-06	0.00436	CrCbGaD
Norethindrone—Insomnia—Doxorubicin—prostate cancer	7.14e-06	0.000127	CcSEcCtD
Norethindrone—Somnolence—Doxorubicin—prostate cancer	7.02e-06	0.000125	CcSEcCtD
Norethindrone—Gastrointestinal pain—Epirubicin—prostate cancer	6.98e-06	0.000125	CcSEcCtD
Norethindrone—Dyspepsia—Doxorubicin—prostate cancer	6.95e-06	0.000124	CcSEcCtD
Norethindrone—Vomiting—Prednisone—prostate cancer	6.94e-06	0.000124	CcSEcCtD
Norethindrone—Rash—Prednisone—prostate cancer	6.88e-06	0.000123	CcSEcCtD
Norethindrone—Dermatitis—Prednisone—prostate cancer	6.88e-06	0.000123	CcSEcCtD
Norethindrone—Headache—Prednisone—prostate cancer	6.84e-06	0.000122	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Doxorubicin—prostate cancer	6.82e-06	0.000122	CcSEcCtD
Norethindrone—Fatigue—Doxorubicin—prostate cancer	6.81e-06	0.000121	CcSEcCtD
Norethindrone—Methyltestosterone—CYP3A4—prostate cancer	6.8e-06	0.00412	CrCbGaD
Norethindrone—Urticaria—Epirubicin—prostate cancer	6.78e-06	0.000121	CcSEcCtD
Norethindrone—Abdominal pain—Epirubicin—prostate cancer	6.75e-06	0.00012	CcSEcCtD
Norethindrone—Progesterone—CYP2C19—prostate cancer	6.56e-06	0.00397	CrCbGaD
Norethindrone—Progesterone—CYP1A1—prostate cancer	6.53e-06	0.00396	CrCbGaD
Norethindrone—Nausea—Prednisone—prostate cancer	6.48e-06	0.000116	CcSEcCtD
Norethindrone—Gastrointestinal pain—Doxorubicin—prostate cancer	6.46e-06	0.000115	CcSEcCtD
Norethindrone—Hypersensitivity—Epirubicin—prostate cancer	6.29e-06	0.000112	CcSEcCtD
Norethindrone—Urticaria—Doxorubicin—prostate cancer	6.28e-06	0.000112	CcSEcCtD
Norethindrone—Abdominal pain—Doxorubicin—prostate cancer	6.24e-06	0.000111	CcSEcCtD
Norethindrone—Testosterone—CYP2C19—prostate cancer	6.2e-06	0.00376	CrCbGaD
Norethindrone—Testosterone—CYP1A1—prostate cancer	6.17e-06	0.00374	CrCbGaD
Norethindrone—Asthenia—Epirubicin—prostate cancer	6.13e-06	0.000109	CcSEcCtD
Norethindrone—Pruritus—Epirubicin—prostate cancer	6.04e-06	0.000108	CcSEcCtD
Norethindrone—Hypersensitivity—Doxorubicin—prostate cancer	5.82e-06	0.000104	CcSEcCtD
Norethindrone—Asthenia—Doxorubicin—prostate cancer	5.67e-06	0.000101	CcSEcCtD
Norethindrone—Dizziness—Epirubicin—prostate cancer	5.65e-06	0.000101	CcSEcCtD
Norethindrone—Pruritus—Doxorubicin—prostate cancer	5.59e-06	9.97e-05	CcSEcCtD
Norethindrone—Vomiting—Epirubicin—prostate cancer	5.43e-06	9.68e-05	CcSEcCtD
Norethindrone—Rash—Epirubicin—prostate cancer	5.38e-06	9.6e-05	CcSEcCtD
Norethindrone—Dermatitis—Epirubicin—prostate cancer	5.38e-06	9.59e-05	CcSEcCtD
Norethindrone—Headache—Epirubicin—prostate cancer	5.35e-06	9.54e-05	CcSEcCtD
Norethindrone—Dizziness—Doxorubicin—prostate cancer	5.22e-06	9.32e-05	CcSEcCtD
Norethindrone—Hydrocortisone—CYP3A4—prostate cancer	5.12e-06	0.0031	CrCbGaD
Norethindrone—Nausea—Epirubicin—prostate cancer	5.07e-06	9.04e-05	CcSEcCtD
Norethindrone—Vomiting—Doxorubicin—prostate cancer	5.02e-06	8.96e-05	CcSEcCtD
Norethindrone—Rash—Doxorubicin—prostate cancer	4.98e-06	8.88e-05	CcSEcCtD
Norethindrone—Dermatitis—Doxorubicin—prostate cancer	4.98e-06	8.88e-05	CcSEcCtD
Norethindrone—Headache—Doxorubicin—prostate cancer	4.95e-06	8.83e-05	CcSEcCtD
Norethindrone—Nausea—Doxorubicin—prostate cancer	4.69e-06	8.37e-05	CcSEcCtD
Norethindrone—Progesterone—CYP3A4—prostate cancer	4.17e-06	0.00253	CrCbGaD
Norethindrone—Testosterone—CYP3A4—prostate cancer	3.94e-06	0.00239	CrCbGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—AKT1—prostate cancer	1.27e-06	5.33e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—AKR1C3—prostate cancer	1.27e-06	5.33e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—SLC5A5—prostate cancer	1.26e-06	5.31e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PRKACB—prostate cancer	1.26e-06	5.3e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PIK3CB—prostate cancer	1.25e-06	5.28e-05	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	1.25e-06	5.25e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP17A1—prostate cancer	1.25e-06	5.25e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP3A5—prostate cancer	1.24e-06	5.23e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—AKR1C3—prostate cancer	1.24e-06	5.2e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP2E1—prostate cancer	1.23e-06	5.19e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—RXRA—prostate cancer	1.23e-06	5.18e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.23e-06	5.17e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PRKACB—prostate cancer	1.23e-06	5.17e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CAV1—prostate cancer	1.22e-06	5.15e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—NQO1—prostate cancer	1.22e-06	5.13e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP17A1—prostate cancer	1.22e-06	5.12e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CXCL8—prostate cancer	1.2e-06	5.07e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—IL2—prostate cancer	1.2e-06	5.07e-05	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.2e-06	5.06e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—TH—prostate cancer	1.2e-06	5.06e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PDHA1—prostate cancer	1.2e-06	5.06e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—TCN2—prostate cancer	1.2e-06	5.06e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTA3—prostate cancer	1.2e-06	5.06e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—UCP3—prostate cancer	1.2e-06	5.06e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.19e-06	5.02e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP3A4—prostate cancer	1.19e-06	5e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NCOA2—prostate cancer	1.19e-06	5e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—COMT—prostate cancer	1.19e-06	4.99e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.18e-06	4.98e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GSTP1—prostate cancer	1.18e-06	4.97e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CDKN1B—prostate cancer	1.18e-06	4.95e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP1B1—prostate cancer	1.17e-06	4.92e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—ITPR1—prostate cancer	1.16e-06	4.89e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NCOA2—prostate cancer	1.16e-06	4.88e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CASP3—prostate cancer	1.15e-06	4.86e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL2—prostate cancer	1.15e-06	4.85e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—SLC22A3—prostate cancer	1.15e-06	4.82e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—HSD3B1—prostate cancer	1.15e-06	4.82e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—SLC5A5—prostate cancer	1.13e-06	4.77e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GGT1—prostate cancer	1.13e-06	4.76e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CCND1—prostate cancer	1.12e-06	4.73e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—NCOA1—prostate cancer	1.11e-06	4.69e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PIK3CG—prostate cancer	1.11e-06	4.69e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CTNNB1—prostate cancer	1.11e-06	4.68e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP2E1—prostate cancer	1.11e-06	4.66e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—SLC5A5—prostate cancer	1.11e-06	4.65e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP19A1—prostate cancer	1.1e-06	4.63e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTA4—prostate cancer	1.1e-06	4.62e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—TBXAS1—prostate cancer	1.1e-06	4.62e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—TYMS—prostate cancer	1.1e-06	4.62e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NQO1—prostate cancer	1.09e-06	4.61e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MMP9—prostate cancer	1.09e-06	4.59e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CDKN1A—prostate cancer	1.09e-06	4.57e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GSTM1—prostate cancer	1.08e-06	4.57e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PTEN—prostate cancer	1.08e-06	4.56e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—EP300—prostate cancer	1.08e-06	4.55e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP2E1—prostate cancer	1.08e-06	4.55e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—TH—prostate cancer	1.08e-06	4.54e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.07e-06	4.51e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTA2—prostate cancer	1.07e-06	4.51e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NQO1—prostate cancer	1.07e-06	4.5e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP3A4—prostate cancer	1.07e-06	4.49e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—LPL—prostate cancer	1.06e-06	4.48e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.06e-06	4.47e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—RXRA—prostate cancer	1.06e-06	4.46e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—SULT1A1—prostate cancer	1.06e-06	4.45e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ABCG5—prostate cancer	1.06e-06	4.45e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—INS—prostate cancer	1.05e-06	4.44e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—TH—prostate cancer	1.05e-06	4.43e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—SRC—prostate cancer	1.05e-06	4.42e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP1B1—prostate cancer	1.05e-06	4.42e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP3A4—prostate cancer	1.04e-06	4.38e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—EP300—prostate cancer	1.03e-06	4.35e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CREBBP—prostate cancer	1.03e-06	4.35e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTA1—prostate cancer	1.03e-06	4.35e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.03e-06	4.34e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYP1A1—prostate cancer	1.03e-06	4.33e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP1B1—prostate cancer	1.02e-06	4.31e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—VEGFA—prostate cancer	1.02e-06	4.31e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—COMT—prostate cancer	1.02e-06	4.3e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—HSD3B2—prostate cancer	1.02e-06	4.3e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTO1—prostate cancer	1.02e-06	4.3e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NAT2—prostate cancer	1.02e-06	4.3e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—ERCC2—prostate cancer	1.02e-06	4.29e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GSTP1—prostate cancer	1.02e-06	4.28e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GGT1—prostate cancer	1.02e-06	4.28e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—SRC—prostate cancer	1e-06	4.23e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NCOA1—prostate cancer	1e-06	4.21e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—ITPR1—prostate cancer	1e-06	4.21e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GGT1—prostate cancer	9.91e-07	4.17e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP19A1—prostate cancer	9.86e-07	4.15e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	9.83e-07	4.14e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PIK3CD—prostate cancer	9.79e-07	4.12e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PLCB2—prostate cancer	9.79e-07	4.12e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—LRP2—prostate cancer	9.79e-07	4.12e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP2C18—prostate cancer	9.79e-07	4.12e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—VEGFA—prostate cancer	9.79e-07	4.12e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NCOA1—prostate cancer	9.77e-07	4.11e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—STAT3—prostate cancer	9.69e-07	4.08e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP19A1—prostate cancer	9.62e-07	4.05e-05	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—AKT1—prostate cancer	9.6e-07	4.04e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—P4HB—prostate cancer	9.6e-07	4.04e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—MTHFR—prostate cancer	9.58e-07	4.04e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—RXRA—prostate cancer	9.52e-07	4.01e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—TYMS—prostate cancer	9.45e-07	3.98e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PPARA—prostate cancer	9.4e-07	3.96e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—TGFB1—prostate cancer	9.39e-07	3.95e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GSTM1—prostate cancer	9.34e-07	3.93e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—SLC22A1—prostate cancer	9.34e-07	3.93e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—RXRA—prostate cancer	9.29e-07	3.91e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	9.26e-07	3.9e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—NOS3—prostate cancer	9.25e-07	3.89e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—LPL—prostate cancer	9.17e-07	3.86e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—COMT—prostate cancer	9.17e-07	3.86e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GSTP1—prostate cancer	9.12e-07	3.84e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—SULT2A1—prostate cancer	9.1e-07	3.83e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MYC—prostate cancer	9e-07	3.79e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TGFB1—prostate cancer	8.98e-07	3.78e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ITPR1—prostate cancer	8.98e-07	3.78e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—MED12—prostate cancer	8.95e-07	3.77e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—COMT—prostate cancer	8.95e-07	3.77e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GSTP1—prostate cancer	8.91e-07	3.75e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GNG5—prostate cancer	8.88e-07	3.74e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP1A1—prostate cancer	8.85e-07	3.73e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CAV1—prostate cancer	8.84e-07	3.72e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	8.83e-07	3.72e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—EGFR—prostate cancer	8.81e-07	3.71e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—ERCC2—prostate cancer	8.78e-07	3.7e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ITPR1—prostate cancer	8.76e-07	3.69e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—KRAS—prostate cancer	8.7e-07	3.66e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NCOA3—prostate cancer	8.55e-07	3.6e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PIK3CB—prostate cancer	8.54e-07	3.59e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—TYMS—prostate cancer	8.48e-07	3.57e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PTGS2—prostate cancer	8.46e-07	3.56e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GSTM1—prostate cancer	8.38e-07	3.53e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—KRAS—prostate cancer	8.32e-07	3.5e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—TYMS—prostate cancer	8.28e-07	3.49e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—MTHFR—prostate cancer	8.25e-07	3.48e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—LPL—prostate cancer	8.23e-07	3.47e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GSTM1—prostate cancer	8.18e-07	3.45e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—HPGDS—prostate cancer	8.16e-07	3.44e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP2C19—prostate cancer	8.11e-07	3.41e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PPARA—prostate cancer	8.1e-07	3.41e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PIK3CG—prostate cancer	8.05e-07	3.39e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—LPL—prostate cancer	8.03e-07	3.38e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PIK3CA—prostate cancer	7.99e-07	3.36e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP1A1—prostate cancer	7.95e-07	3.35e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTT1—prostate cancer	7.92e-07	3.33e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ACHE—prostate cancer	7.92e-07	3.33e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ERCC2—prostate cancer	7.88e-07	3.32e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP2A6—prostate cancer	7.82e-07	3.29e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP1A1—prostate cancer	7.76e-07	3.27e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—TP53—prostate cancer	7.73e-07	3.25e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ERCC2—prostate cancer	7.69e-07	3.24e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PIK3CA—prostate cancer	7.64e-07	3.22e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—INS—prostate cancer	7.62e-07	3.21e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CAV1—prostate cancer	7.61e-07	3.21e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—AKR1C3—prostate cancer	7.61e-07	3.2e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PRKACB—prostate cancer	7.57e-07	3.19e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP17A1—prostate cancer	7.49e-07	3.15e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CREBBP—prostate cancer	7.47e-07	3.14e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—MTHFR—prostate cancer	7.41e-07	3.12e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TP53—prostate cancer	7.39e-07	3.11e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PTEN—prostate cancer	7.38e-07	3.11e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	7.27e-07	3.06e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PPARA—prostate cancer	7.27e-07	3.06e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—MTHFR—prostate cancer	7.23e-07	3.05e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NCOA2—prostate cancer	7.14e-07	3.01e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PPARA—prostate cancer	7.1e-07	2.99e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PIK3CD—prostate cancer	7.08e-07	2.98e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—EP300—prostate cancer	7.03e-07	2.96e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PIK3CG—prostate cancer	6.94e-07	2.92e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CAV1—prostate cancer	6.83e-07	2.88e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—SLC5A5—prostate cancer	6.81e-07	2.87e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL6—prostate cancer	6.77e-07	2.85e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—NOS3—prostate cancer	6.68e-07	2.81e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CAV1—prostate cancer	6.67e-07	2.81e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP2E1—prostate cancer	6.65e-07	2.8e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NQO1—prostate cancer	6.58e-07	2.77e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—INS—prostate cancer	6.56e-07	2.76e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.53e-07	2.75e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—AKT1—prostate cancer	6.53e-07	2.75e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—TH—prostate cancer	6.48e-07	2.73e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CREBBP—prostate cancer	6.43e-07	2.71e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP1B1—prostate cancer	6.31e-07	2.66e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—AKT1—prostate cancer	6.24e-07	2.63e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PIK3CG—prostate cancer	6.23e-07	2.62e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PIK3CB—prostate cancer	6.17e-07	2.6e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PTGS2—prostate cancer	6.11e-07	2.57e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GGT1—prostate cancer	6.11e-07	2.57e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PIK3CD—prostate cancer	6.1e-07	2.57e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PIK3CG—prostate cancer	6.08e-07	2.56e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NCOA1—prostate cancer	6.02e-07	2.53e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP19A1—prostate cancer	5.93e-07	2.5e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—INS—prostate cancer	5.89e-07	2.48e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CREBBP—prostate cancer	5.77e-07	2.43e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—NOS3—prostate cancer	5.76e-07	2.42e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—INS—prostate cancer	5.75e-07	2.42e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—RXRA—prostate cancer	5.72e-07	2.41e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CREBBP—prostate cancer	5.63e-07	2.37e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—COMT—prostate cancer	5.51e-07	2.32e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTP1—prostate cancer	5.49e-07	2.31e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PIK3CD—prostate cancer	5.47e-07	2.3e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ITPR1—prostate cancer	5.4e-07	2.27e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PIK3CD—prostate cancer	5.34e-07	2.25e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PTEN—prostate cancer	5.33e-07	2.25e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PIK3CB—prostate cancer	5.31e-07	2.24e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PTGS2—prostate cancer	5.27e-07	2.22e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PIK3CA—prostate cancer	5.2e-07	2.19e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NOS3—prostate cancer	5.17e-07	2.18e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—TYMS—prostate cancer	5.1e-07	2.15e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—EP300—prostate cancer	5.08e-07	2.14e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NOS3—prostate cancer	5.04e-07	2.12e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTM1—prostate cancer	5.04e-07	2.12e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—LPL—prostate cancer	4.95e-07	2.08e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP1A1—prostate cancer	4.78e-07	2.01e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PIK3CB—prostate cancer	4.77e-07	2.01e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ERCC2—prostate cancer	4.74e-07	2e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PTGS2—prostate cancer	4.73e-07	1.99e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PIK3CB—prostate cancer	4.66e-07	1.96e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PTGS2—prostate cancer	4.61e-07	1.94e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PTEN—prostate cancer	4.59e-07	1.93e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—MTHFR—prostate cancer	4.46e-07	1.88e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—EP300—prostate cancer	4.38e-07	1.84e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PPARA—prostate cancer	4.37e-07	1.84e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—AKT1—prostate cancer	4.25e-07	1.79e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PTEN—prostate cancer	4.12e-07	1.74e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CAV1—prostate cancer	4.11e-07	1.73e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PTEN—prostate cancer	4.02e-07	1.69e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—EP300—prostate cancer	3.93e-07	1.66e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—EP300—prostate cancer	3.84e-07	1.62e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PIK3CA—prostate cancer	3.76e-07	1.58e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.74e-07	1.58e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—INS—prostate cancer	3.54e-07	1.49e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CREBBP—prostate cancer	3.47e-07	1.46e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PIK3CD—prostate cancer	3.29e-07	1.39e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PIK3CA—prostate cancer	3.24e-07	1.36e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NOS3—prostate cancer	3.11e-07	1.31e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—AKT1—prostate cancer	3.07e-07	1.29e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PIK3CA—prostate cancer	2.91e-07	1.22e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.87e-07	1.21e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PTGS2—prostate cancer	2.84e-07	1.2e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PIK3CA—prostate cancer	2.84e-07	1.2e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—AKT1—prostate cancer	2.65e-07	1.11e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PTEN—prostate cancer	2.48e-07	1.04e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—AKT1—prostate cancer	2.38e-07	1e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—EP300—prostate cancer	2.36e-07	9.95e-06	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—AKT1—prostate cancer	2.32e-07	9.76e-06	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.75e-07	7.36e-06	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—AKT1—prostate cancer	1.43e-07	6.02e-06	CbGpPWpGaD
